Abstracts tagged "anti-TNF therapy"

Abstract Number: 712 • 2016 ACR/ARHP Annual Meeting
Efficacy of Golimumab for Nonradiographic Axial Spondyloarthritis (nr-axSpA): Subgroup Analysis By Baseline MRI and C-Reactive Protein Status
Joachim Sieper¹, Désirée van der Heijde², Walter Maksymowych³, Jürgen Braun⁴, G Bergman⁵, Sean P. Curtis⁶, Anjela Tzontcheva⁶, George Philip⁶, Susan Huyck⁶ and Maxime Dougados⁷, ¹Rheumatology Department, Charité – University Medicine Berlin, Berlin, Germany, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Medicine, University of Alberta,, Edmonton, AB, Canada, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Merck & Co., Inc., Whitehouse Station, NJ, ⁶Merck & Co., Inc., Kenilworth, NJ, ⁷Paris-Descartes University, Paris, France
Background/Purpose: Efficacy of golimumab (GLM) for nr-axSpA was demonstrated in a randomized, double-blind (DB), placebo (PBO)-controlled, phase 3 study (GO-AHEAD; NCT01453725).1 In a subgroup analysis,…
Abstract Number: 2148 • 2016 ACR/ARHP Annual Meeting
Recruitment of Circulating Monocytes By TNF/IL-6-Induced Expression of Vascular Cell Adhesion Molecule 1 (VCAM-1) Drives Valvular Inflammation in K/B/g7 Mice
Lee Meier¹, Jennifer L. Auger², Brianna J. Engelson³, Elise Breed⁴, Joshua Boyer⁵ and Bryce A. Binstadt², ¹Peadiatrics, University of Minnesota, Minneapols, MN, ²Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN, ³Pediatrics, University of Minnesota, Minneapolis, MN, ⁴Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, ⁵Medicine, University of Minnesota, Minneapolis, MN
Background/Purpose: Cardiovascular (CV) comorbidity is common in rheumatic diseases and includes accelerated atherosclerosis and inflammatory valvular heart disease (iVHD). KRN T cell receptor (TCR) transgenic…
Abstract Number: 2987 • 2016 ACR/ARHP Annual Meeting
Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study
Roy Fleischmann¹, Gerd-Rüdiger Burmester², Bernard Combe³, Jeffrey R. Curtis⁴, Stephen Hall⁵, Boulos Haraoui⁶, Ronald van Vollenhoven⁷, Christopher Cioffi⁸, Cécile Ecoffet⁹, Lucian Ionescu⁹, Leon Gervitz¹⁰, Luke Peterson⁸ and Josef Smolen¹¹, ¹University of Texas Southwestern Medical Center at Dallas Metroplex Clinical Research Center, Dallas, TX, ²Charité – University Medicine Berlin, Berlin, Germany, ³Montpellier University Hospital, Montpellier, France, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Cabrini Medical Centre, Monash University, Melbourne, Australia, ⁶Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁷Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Brussels, Belgium, ¹⁰RA Patient Value Mission, UCB Pharma, Brussels, Belgium, ¹¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Head-to-head comparisons of biological (b)DMARDs in the treatment of RA should provide rigorous evidence on the comparative efficacy of different treatments. Although there are…
Abstract Number: 532 • 2016 ACR/ARHP Annual Meeting
The DAS28 Score May Misread Disease Activity in Rheumatoid Arthritis Patients
Abdul Khan¹ and Apostolos Vrettos², ¹Rheumatology, East Kent University Hospital NHS Foundation Trust, Queen Elizabeth Queen Mother Hospital, Margate, United Kingdom, ²Rheumatology, Queen Elizabeth Queen Mother Hospital, Margate, United Kingdom
Background/Purpose: The DAS28 is a measure of disease activity in rheumatoid arthritis (RA). DAS28 stands for 'disease activity score' and the number 28 refers to…
Abstract Number: 728 • 2016 ACR/ARHP Annual Meeting
Correlation Between the Spinal MRI Findings and the Serum Level of DKK-1 in Patients with Spondyloarthritis Treated with TNF Antagonist
Zheng Zhao, Gang Wang, Yanyan Wang, Jinshui Yang, Jian Zhu and Feng Huang, Rheumatology, Chinese PLA General Hospital, Beijing, China
Background/Purpose : Recent prospective data suggest that spinal inflammatory damage in patients with ankylosing spondylitis will eventually convert into fat. In these complex inflammatory lesions,…
Abstract Number: 2232 • 2016 ACR/ARHP Annual Meeting
Above-Label Dosing with Biologics in Treatment-NaïVe and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis
Sergio Schwartzman¹, Yunfeng Li², Huanxue Zhou³, Vivian Herrera² and Jacqueline B. Palmer², ¹Hospital for Special Surgery, New York, NY, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³KMK Consulting Inc, East Hanover, NJ
Title: Above-Label Dosing with Biologics in Treatment-Naïve and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis Authors: S. Schwartzman*1, Y. Li2, H. Zhou3, V. Herrera2, J. Palmer2…
Abstract Number: 3014 • 2016 ACR/ARHP Annual Meeting
Tapering of Adalimumab Based on Therapeutic Drug Monitoring in Rheumatoid Arthritis
Merel J. l'Ami¹, Anneke F. Marsman¹, Charlotte LM Krieckaert¹, Mike T. Nurmohamed^2,3, Jill Ruwaard¹, Ingrid M. Visman¹, Eva L. Kneepkens¹ and Gertjan Wolbink^1,4, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁴Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Center, Amsterdam, Netherlands
Background/Purpose: Treatment with biologicals is based on the principle of ‘one size fits all’ without taking differences into account for dosing schemes, patients’ characteristics and…
Abstract Number: 595 • 2016 ACR/ARHP Annual Meeting
Cinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
Vivian P. Bykerk¹, Paul Emery², Michael Weinblatt³, Gerd-Rüdiger Burmester⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Ronald van Vollenhoven⁷, Oana Purcaru⁸, Pauline Ralston⁹ and Clifton Bingham III¹⁰, ¹Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ²University of Leeds, Midlothian, United Kingdom, ³Brigham and Women’s Hospital, Boston, MA, ⁴Charité – University Medicine Berlin, Berlin, Germany, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Université Paris-Sud, Paris, France, ⁷Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁸UCB Pharma, Slough, United Kingdom, ⁹Hays Pharma, London, United Kingdom, ¹⁰Johns Hopkins University, Baltimore, MD
Background/Purpose: Rheumatoid arthritis (RA) is associated with work disability, loss of productivity and reduced quality of life. In established and early RA, compared with MTX…
Abstract Number: 916 • 2016 ACR/ARHP Annual Meeting
Novel Immunosignature Stratifies Patients with Rheumatoid Arthritis into Distinct Disease Sub-Groups and Predicts Response to Anti-Tnfα Therapies
Laura Magill¹, Marsilio Adriani¹, Victoria Howard², Jessica Manson², Elizabeth Jury³ and Claudia Mauri⁴, ¹University College London, London, United Kingdom, ²University College London Hospitals NHS Trust, London, United Kingdom, ³Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴Division of Medicine, Centre for Rheumatology Research, University College London, University College London, London, United Kingdom
Background/Purpose: Autoimmune rheumatic diseases, including rheumatoid arthritis (RA), have multifactorial pathogenesis associated with failure of immune tolerance. Advances in understanding the disease immunopathology have led…
Abstract Number: 2234 • 2016 ACR/ARHP Annual Meeting
Economic Impact of Above-Label Dosing with Biologics in Patients with Moderate-to-Severe Psoriatic Arthritis
Sergio Schwartzman¹, Yunfeng Li², Huanxue Zhou³, Vivian Herrera² and Jacqueline B. Palmer², ¹Hospital for Special Surgery, New York, NY, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³KMK Consulting Inc, East Hanover, NJ
Authors: S. Schwartzman*1, Y. Li2, H. Zhou3, V. Herrera2, J. Palmer2 Affiliations: 1Hospital for Special Surgery, New York, NY, US; 2Novartis Pharmaceuticals Corporation, East Hanover,…
Abstract Number: 3065 • 2016 ACR/ARHP Annual Meeting
Mortality in Patients with Rheumatoid Arthritis and Interstitial Lung Disease Treated with First Line TNFi or Rituximab Therapies
Katie Druce¹, Kundan Iqbal², Kath Watson¹, Deborah P.M. Symmons¹, Kimme L. Hyrich¹ and Clive Kelly³, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Newcastle University, Newcastle, United Kingdom, ³Rheumatology, Queen Elizabeth Hospital, Gateshead, United Kingdom
Mortality in Patients With Rheumatoid Arthritis and Interstitial Lung Disease Treated With First Line TNFi or Rituximab Therapies Druce KL, Iqbal K, Watson K, Symmons…
Abstract Number: 89 • 2015 ACR/ARHP Annual Meeting
A Longitudinal Genome-Wide Association Study of Anti-Tumor Necrosis Factor Response Among Japanese Patients with Rheumatoid Arthritis
Kyoko Honne¹, Ingileif Hallgrimsdottir², Chunsen Wu³, Ronnie Sebro⁴, Nicholas Jewell², Takeo Sakurai⁵, Masahiro Iwamoto⁶, Seiji Minota⁶ and Damini Jawaheer⁷, ¹Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ²UC Berkeley, Berkeley, CA, ³University of Southern Denmark, Odense, Denmark, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Inoue Hospital, Takasaki, Japan, ⁶Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ⁷Children's Hospital Oakland Research Institute, Oakland, CA
Background/Purpose: Studies of patients with rheumatoid arthritis (RA) to identify genetic biomarkers of anti-tumor necrosis factor (TNF) response have been conducted mostly in Caucasian populations.…
Abstract Number: 654 • 2015 ACR/ARHP Annual Meeting
Associations Between Skin Outcomes By Body Area Affected and Health-Related Quality of Life in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol
Alice B. Gottlieb¹, Bengt Hoepken², Luke Peterson³ and Peter C. Taylor⁴, ¹Dermatology, Tufts Medical Center, Boston, MA, ²UCB Pharma, Monheim, Germany, ³UCB Pharma, Raleigh, NC, ⁴Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) report poorer health-related quality of life (HRQoL) compared to the general population. As with psoriasis (PSO), it is…
Abstract Number: 1637 • 2015 ACR/ARHP Annual Meeting
TNFi Combination Therapy, Switching and Persistence Patterns By Longitudinal Disease Activity Strata in Patients with Rheumatoid Arthritis
Leslie Harrold^1,2, George W. Reed^1,2, Natalie Boytsov³, Carol L. Gaich³, Marc Mason⁴, Xiang Zhang³, Cynthia J. Larmore³, Sabrina Deveikis⁴ and Andre B. Araujo³, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Corrona, LLC., Southborough, MA
Background/Purpose: The purpose of this study was to describe the treatment patterns in biologic naïve initiators of TNF-inhibitors (TNFi) based on their disease activity over…
Abstract Number: 2734 • 2015 ACR/ARHP Annual Meeting
Validation and Comparison Study of Immunoassays for the Measurement of Golimumab and Antibodies to Golimumab in Rheumatic Patients
Sergio Martín^1,2, Ainhoa Ruiz del Agua¹, Nerea Torres¹, Dora Pascual-Salcedo³, Chamaida Plasencia⁴, Teresa Jurado⁵, Begoña Ruiz-Argüello¹, Antonio Martínez¹, Rosaura Navarro⁶ and Daniel Nagore¹, ¹R&D, Progenika-Grifols, Derio, Spain, ²Department of Physiology, Medicine and Dentistry School, University of the Basque Country UPV/EHU (Convocatoria ZabaldUZ, UPV/EHU; Departamento de Educación, Universidades e Investigación del Gobierno Vasco, Ref. IT687-13), Leioa, Spain, ³Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ⁴Rheumatology Unit, La Paz University Hospital-Rheumatology, Madrid, Spain, ⁵Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁶Department of Physiology, Medicine and Dentistry School, University of the Basque Country UPV/EHU, Leioa, Spain
Background/Purpose: The options for treatment of rheumatoid arthritis (RA) with tumour necrosis factor (TNF) inhibitors is constantly growing. As a consequence monitoring of drug levels (DL)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.